

Press release from Emotra AB (publ)
Göteborg, December 17, 2014

Emotra has been granted an “EU card” by the Västra Götaland region

Emotra received a positive response from Västra Götaland Region (VGR) regarding the application for an “EU card”. This card represents financial support from VGR to help innovative companies from West Sweden prepare to apply for EU aid. The card amount comes to SEK 150K and is to be used to finance Emotra's work and preparations to apply for money from the EU Horizon 2020 programme. Emotra intends to submit an application to the EU for €50K to finance a feasibility study to demonstrate the potential of broadening the EDOR indication range to include children and teenagers up to 18 years of age.

Efforts to put together an application for funding for the feasibility study have been underway for some time and are scheduled to be submitted to the EU by no later than 17th March 2015. Putting together an application for money from the EU is painstaking and costly. The positive response from VGR means that these efforts can now be continued without running the risk of using up the company's cash.

The feasibility study will take a maximum of 6 months and, if it shows good potential, an application for a full study will be submitted. The EU can finance a complete study with up to €5M. The EU has decided that Horizon 2020 will focus on small and medium-sized companies that have the potential to contribute to the creation of more jobs, good business opportunities, better health and improved quality of life for the EU population.

Emotra's Board of Directors believes that the EU's new focus significantly strengthens Emotra's chances of taking part in the extensive grants awarded for research and development. If Emotra manages to go all the way and has costs covered for a research project demonstrating that EDOR is also effective on children up until the age of 18, this would mean that the company could save itself a lot of time. Without EU funding, the company would have to postpone this kind of study until it could be funded by sales.

With EU funding, a study in children and teenagers up until the age of 18 could be up and running in just over a year.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.